Method of Treatment of Tumors That Are Resistant to EGFR Therapies by EGFR Antibody Cytotoxic Agent Conjugate
AssigneeImmunoGen, Inc.
InventorsJulianto SETIADY, Peter U. Park, Thomas Chittenden
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor cells that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant tumor cells is also disclosed.
Claims33
A method of inhibiting the growth of epidermal growth factor receptor (EGFR)-expressing tumor cells that are resistant or refractory to EGFR therapy, said method comprising contacting said tumor cells with an effective amount of an EGFR antibody immunoconjugate.
A method of treating cancer in a patient comprising administering an effective amount of an EGFR antibody immunoconjugate to inhibit growth of the tumor cells in said patient, wherein at least one of the tumor cells:
- (1) contains one or more mutations in an EGFR-encoding gene;
- (2) contains one or more mutations in a PIK3CA, RAS, or PTEN encoding gene;
- (3) has an activated MET or IGF1R pathway;
- (4) has mesenchymal histology or has undergone epithelial-mesenchymal transition;
- or (5) has ERBB2 gene amplification or increased production of HER2 protein.
A method of treating cancer in a patient comprising:
- (a) identifying tumor cells from said patient that (1) contain one or more mutations in an EGFR-encoding gene;
- (2) contain one or more mutations in a PIK3CA, RAS, or PTEN encoding gene;
- (3) have an activated MET or IGF1R pathway;
- or (4) have mesenchymal histology or have undergone epithelial-mesenchymal transition;
- and
- (b) administering an effective amount of an EGFR antibody immunoconjugate to said patient.
A method of treating cancer in a patient comprising administering an effective amount of an EGFR antibody immunoconjugate to inhibit growth of the tumor cells in said patient, wherein at least one of the tumor cells is resistant to therapy comprising an anaplastic lymphoma kinase (ALK) inhibitor.
A method of treating cancer in a patient comprising:
- (a) identifying tumor cells from said patient that are resistant to at least one ALK inhibitor;
- and
- (b) administering an effective amount of an EGFR antibody immunoconjugate to said patient.
Dependencies are inferred from the claim text.